TRAVERE THERAPEUTICS, INC. Current Income Tax Expense (Benefit)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Current Income Tax Expense (Benefit) of $988.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2025 was $988.00K, a 723.33% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2024 was $120.00K, a 46.19% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2023 was $223.00K, a 28.75% decline from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. current income tax expense (benefit) for fiscal 2022 was $313.00K, a 23.47% decline from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $988.00K 10-K · filed 2026-02-19 |
| 2024-12-31 | $120.00K 10-K · filed 2026-02-19 |
| 2023-12-31 | $223.00K 10-K · filed 2026-02-19 |
| 2022-12-31 | $313.00K 10-K · filed 2025-02-21 |
| 2021-12-31 | $409.00K 10-K · filed 2024-02-20 |
| 2020-12-31 | -$19.36M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$21.00K 10-K · filed 2022-02-24 |
| 2018-12-31 | $811.00K 10-K · filed 2021-03-01 |
| 2017-12-31 | $7.79M 10-K · filed 2020-02-24 |
| 2016-12-31 | $12.98M 10-K · filed 2019-02-26 |
| 2015-12-31 | $3.80M 10-K · filed 2018-07-06 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |